JPMorgan analyst Tessa Romero raised the firm’s price target on Biohaven to $32 from $26 and keeps an Overweight rating on the shares. The analyst believes investor interest is building around the company’s degrader platform. Holding a “vast portfolio” with potentially de-risking shots on goal in 2024 and beyond, Biohaven is an attractive stock for investors looking for growth, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BHVN:
- Biohaven price target raised to $36 from $29 at Piper Sandler
- Biohaven reports Q3 adjusted EPS ($1.44), consensus ($1.34)
- Fly Insider: Biohaven, BJ’s Wholesale Club among weeks’ notable insider trades
- Biohaven reported preclinical data from study of taldefgrobep alfa
- Biotech Alert: Searches spiking for these stocks today